Bris­tol My­ers ex­pands Cel­gene-era deal with Ex­sci­en­tia, tak­ing its AI R&D en­gine to the next step

One day af­ter tak­ing a shot on an an­ti-TIG­IT bis­pe­cif­ic from Agenus, Bris­tol My­ers Squibb is still in a deal­mak­ing mood.

For Wednes­day’s chas­er, Bris­tol My­ers is re­turn­ing to a com­pa­ny that had teamed up with Cel­gene be­fore its ac­qui­si­tion in 2019. That biotech is Ex­sci­en­tia, and they’ve scored an ex­pand­ed deal with Bris­tol My­ers to fur­ther build on its ar­ti­fi­cial in­tel­li­gence ca­pa­bil­i­ties less than a month af­ter a mas­sive Se­ries D fi­nanc­ing.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER